Validation of LC-MS electrospray ionisation method for quantitation of haloperidol in human plasma and its application to bioequivalence study
Validation of LC-MS electrospray ionisation method for quantitation of haloperidol in human plasma and its application to bioequivalence study
复制标题
LC-MS 电喷雾电离法定量人血浆中氟哌啶醇的验证及其在生物等效性研究中的应用
DOI:
10.1016/j.aca.2005.07.046
复制
发表时间:
2005
影响因子:
6.2
通讯作者:
Kuldeep Sharma
中科院分区:
文献类型:
--
作者:
S. S. Singh;Kuldeep Sharma
In the present investigation, a new sensitive LC/MS electrospray ionisation mass spectrometric method has been developed for the quantitation of haloperidol—an antipsychotic drug, in human plasma. The method was developed with the objective of accurately measuring the concentration of haloperidol in the plasma of human subjects enrolled in the bioequivalence study of haloperidol (5mg) tablets of M/s. Cadila Health Care Ltd. India versus 5mg haloperidol tablets of Geneva Pharma USA. The sample purification and pre-concentration was performed by liquid–liquid extraction (LLE) using duloxetine as internal standard. The chromatographic separation was achieved using an isocratic mobile phase containing 1.0mM ammonium acetate pH 3.0 and acetonitrile (70:30, v/v) flowing through Xterra MS C18 100mm×2.1mm, 3.5μm analytical column, at a flow rate of 0.2ml/min. The lower limit of quantitation (LLOQ) of 70.0pg/ml was achieved using mass spectrometric detection in positive mode. The ion signals of m/z 375.9 and 297.9 were measured for haloperidol and internal standard, respectively. An exhaustive pre-study method validation was performed in accordance with USFDA guidelines. The standard curves were linear in the concentration range of 70.0pg/ml to 14.0ng/ml with mean correlation coefficient of 0.998. The method was successfully applied to the bioequivalence study of haloperidol in healthy human male volunteers.